Tags

Type your tag names separated by a space and hit enter

Plasma biomarkers of Alzheimer's disease.
Curr Opin Psychiatry. 2008 May; 21(3):260-7.CO

Abstract

PURPOSE OF REVIEW

The importance of biomarkers of Alzheimer's disease is increasing. The present review aims to offer a general view of plasma biomarkers of Alzheimer's disease and to discuss their relevance and limitations.

RECENT FINDINGS

The broad overlap in the plasma amyloid beta protein (Abeta) levels between patients with Alzheimer's disease and control individuals indicates that the plasma Abeta level cannot differentiate cases of sporadic Alzheimer's disease from control cases. Although the significance of Abeta for diagnosing Alzheimer's disease is controversial, high plasma concentrations of Abeta40 and low plasma concentrations of Abeta42 indicate an increased risk of dementia.

SUMMARY

The usefulness of biomarkers in cerebrospinal fluid has been shown by numerous studies; this test is not commonly used, however, and blood biomarkers are therefore preferred. Increasing evidence shows that the plasma Abeta concentration may be a premorbid marker for the risk of Alzheimer's disease. It may be used for therapeutic monitoring, diagnosis of Abeta deposition in the brain, and also as a surrogate genetic marker to identify novel genetic determinants of Alzheimer's disease. A potential role of plasma Abeta concentration as a marker of incipient dementia warrants further investigation.

Authors+Show Affiliations

Department of Neurology, Hirosaki University Graduate School of Medicine, Institute of Brain Science, 5 Zaifu-cho, Hirosaki, Japan. tkawara@cc.hirosaki-u.ac.jpNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18382225

Citation

Kawarabayashi, Takeshi, and Mikio Shoji. "Plasma Biomarkers of Alzheimer's Disease." Current Opinion in Psychiatry, vol. 21, no. 3, 2008, pp. 260-7.
Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimer's disease. Curr Opin Psychiatry. 2008;21(3):260-7.
Kawarabayashi, T., & Shoji, M. (2008). Plasma biomarkers of Alzheimer's disease. Current Opinion in Psychiatry, 21(3), 260-7. https://doi.org/10.1097/YCO.0b013e3282fc989f
Kawarabayashi T, Shoji M. Plasma Biomarkers of Alzheimer's Disease. Curr Opin Psychiatry. 2008;21(3):260-7. PubMed PMID: 18382225.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma biomarkers of Alzheimer's disease. AU - Kawarabayashi,Takeshi, AU - Shoji,Mikio, PY - 2008/4/3/pubmed PY - 2008/7/25/medline PY - 2008/4/3/entrez SP - 260 EP - 7 JF - Current opinion in psychiatry JO - Curr Opin Psychiatry VL - 21 IS - 3 N2 - PURPOSE OF REVIEW: The importance of biomarkers of Alzheimer's disease is increasing. The present review aims to offer a general view of plasma biomarkers of Alzheimer's disease and to discuss their relevance and limitations. RECENT FINDINGS: The broad overlap in the plasma amyloid beta protein (Abeta) levels between patients with Alzheimer's disease and control individuals indicates that the plasma Abeta level cannot differentiate cases of sporadic Alzheimer's disease from control cases. Although the significance of Abeta for diagnosing Alzheimer's disease is controversial, high plasma concentrations of Abeta40 and low plasma concentrations of Abeta42 indicate an increased risk of dementia. SUMMARY: The usefulness of biomarkers in cerebrospinal fluid has been shown by numerous studies; this test is not commonly used, however, and blood biomarkers are therefore preferred. Increasing evidence shows that the plasma Abeta concentration may be a premorbid marker for the risk of Alzheimer's disease. It may be used for therapeutic monitoring, diagnosis of Abeta deposition in the brain, and also as a surrogate genetic marker to identify novel genetic determinants of Alzheimer's disease. A potential role of plasma Abeta concentration as a marker of incipient dementia warrants further investigation. SN - 0951-7367 UR - https://www.unboundmedicine.com/medline/citation/18382225/Plasma_biomarkers_of_Alzheimer's_disease_ L2 - https://doi.org/10.1097/YCO.0b013e3282fc989f DB - PRIME DP - Unbound Medicine ER -